Back

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway

Gu, X.; Biswas, S.; Zahran, Z. A.; Bae, S.; Balusu, R.; Jha, B. K.; Maciejewski, J. P.; Saunthararajah, Y.

2026-07-15 cancer biology
10.64898/2026.07.14.738455 bioRxiv
Show abstract

Internal-tandem-duplication of the receptor tyrosine kinase FLT3 (FLT3-ITD) generates ligand-independent signaling and is highly recurrent in acute myeloid leukemias (AMLs). One way signaling pathways can quickly influence cell fates is by phosphorylating key fate-determining proteins to trigger their proteolysis. We investigated the master transcription factor (MTF) driver of granulo-monocytic lineage-fates, CEBPA, for regulation by this mechanism because we found high CEBPA mRNA but little CEBPA protein in FLT3-ITD versus FLT3-wildtype AML cells, and inhibiting FLT3-ITD signaling with tyrosine kinase inhibitors (TKI) rapidly rescued CEBPA protein. Mass spectrometry analyses of CEBPA and its interactome demonstrated prominent interactions with major ubiquitin-proteosome pathway (UPP) components UHRF1 and USP7. TKI treatments decreased CEBPA and USP7 phosphorylations at serine 21 and serine 18 respectively alongside shifts in CEBPA interactions from degradative ubiquitin-ligase UHRF1 toward protective deubiquitinase USP7. The rescued CEBPA activated granulocytic-differentiation. Supporting that the serine-phosphorylations were phospho-degrons, UPP-inhibitors (bortezomib, MG132) increased phosphorylated and total CEBPA and USP7. The MTF regulator of apoptosis p53 is a known USP7 client, therefore, we also evaluated p53 status: TKIs and UPP-inhibitors stabilized USP7 and p53, triggering apoptosis in addition to granulocytic-differentiation specifically in FLT3-ITD but not FLT3-wildtype AML cells. UPP-inhibitors produced these consequences in TKI-resistant FLT3-ITD AML cells also. These data predicted genetic loss-of-function to CEBPA or TP53 is redundant in the FLT3-ITD context, borne out by mutual exclusivity of the mutations in clinical series. In summary, FLT3-ITD signals for CEBPA and p53 proteolysis to block lineage-maturation and apoptosis, positioning UPP-inhibitors as therapeutic candidates acting downstream of TKIs. KEY POINTSO_LIThe oncoprotein kinase FLT3-ITD signals for CEBPA and p53 proteolysis and hence suppresses lineage-differentiation and apoptosis C_LIO_LIProteosome-inhibitors are candidate remedies to restore CEBPA and p53, acting downstream of presently used FLT3-ITD kinase inhibitors C_LI GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=171 SRC="FIGDIR/small/738455v1_ufig1.gif" ALT="Figure 1"> View larger version (56K): org.highwire.dtl.DTLVardef@6ae211org.highwire.dtl.DTLVardef@12003bforg.highwire.dtl.DTLVardef@d62eb9org.highwire.dtl.DTLVardef@1958693_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Leukemia
42 papers in training set
Top 0.1%
9.7%
2
Cell Death & Disease
21 papers in training set
Top 0.1%
7.2%
3
Blood Advances
62 papers in training set
Top 0.2%
7.2%
4
HemaSphere
16 papers in training set
Top 0.1%
4.8%
5
Blood
74 papers in training set
Top 0.5%
4.3%
6
Haematologica
25 papers in training set
Top 0.2%
4.0%
7
Oncogene
85 papers in training set
Top 0.5%
3.5%
8
Nature Communications
5641 papers in training set
Top 36%
3.2%
9
Cell Reports
1498 papers in training set
Top 12%
3.2%
10
eLife
5828 papers in training set
Top 35%
3.2%
50% of probability mass above
11
Science Advances
1243 papers in training set
Top 14%
2.4%
12
Molecular Oncology
55 papers in training set
Top 0.4%
2.4%
13
Cancers
213 papers in training set
Top 2%
2.4%
14
PLOS ONE
5266 papers in training set
Top 47%
1.9%
15
International Journal of Molecular Sciences
494 papers in training set
Top 7%
1.9%
16
Cell Communication and Signaling
51 papers in training set
Top 0.5%
1.7%
17
Cell Death & Disease
126 papers in training set
Top 2%
1.7%
18
Clinical Cancer Research
64 papers in training set
Top 1%
1.7%
19
Oncogenesis
12 papers in training set
Top 0.2%
1.3%
20
EMBO Molecular Medicine
95 papers in training set
Top 1%
1.3%
21
Frontiers in Immunology
638 papers in training set
Top 8%
1.1%
22
Scientific Reports
3612 papers in training set
Top 65%
1.1%
23
Molecular Cancer Research
49 papers in training set
Top 1%
1.1%
24
Cancer Discovery
66 papers in training set
Top 2%
1.0%
25
Cell Death Discovery
58 papers in training set
Top 1%
1.0%
26
Molecular and Cellular Biology
47 papers in training set
Top 0.7%
1.0%
27
PLOS Pathogens
820 papers in training set
Top 8%
1.0%
28
PLOS Genetics
862 papers in training set
Top 11%
1.0%
29
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.6%
1.0%
30
Clinical Epigenetics
60 papers in training set
Top 0.5%
0.9%